CAPRIE21 | 19185 | Symptomatic atherosclerotic disease (peripheral or cerebral disease or IHD) | Aspirin 325 mg v clopidogrel 75 mg | Composite event*: 5.32% clopidogrel v 5.83% aspirin | 0.043 |
| | In patients with PVD: 3.71% clopidogrel v 4.86% aspirin | 0.0028 |
CURE22 | 12562 | ACS without ST segment elevation | Clopidogrel (300 mg bolus followed by 75 mg daily for up to 1 year) and aspirin v placebo and aspirin | First primary outcome†: 9.3% clopidogrel v 11.4% placebo | <0.001 |
| | | | Second primary outcome‡: 16.5% clopidogrel v 18.8% placebo | <0.001 |
PCI-CURE§26 | 2658 | PCI (at physician’s discretion) in CURE patients | Clopidogrel and aspirin v placebo and aspirin. Patients requiring stents received open labelled thienopyridine for 2–4 weeks after the procedure | Primary outcome¶: 4.5% clopidogrel v 6.4% placebo | 0.03 |
CREDO8 | 2116 | Patients undergoing elective PCI (including 1117 with unstable angina) | Clopidogrel 300 mg loading dose or placebo before PCI. All patients received aspirin and clopidogrel for 1 month after PCI. Aspirin + clopidogrel v aspirin + placebo after 1 month until 1 year | 28 day primary outcome**: 6.8% clopidogrel v 8.3% placebo 1 year primary outcome††: 8.5% clopidogrel v placebo 11.5% | 0.23 0.02 |
| | | | |